"Eli Lilly (NYSE:LLY) has quickly emerged as one of Wall Street's biggest winners, fueled by explosive demand for its new generation of weight-loss and diabetes treatments. The company's GLP-1 drugs, including Mounjaro and the newly approved Zepbound, have turned into blockbuster products, generating billions in sales and reshaping the pharmaceutical landscape. As a result, Eli Lilly's stock surged more than 50% year-to-date in 2024."
"Despite lofty valuations (trading at more than 30 times forward earnings) investors remain bullish on Lilly's prospects. In 2024, analysts saw potential for the company's market capitalization to approach $1 trillion. However, in 2025, Eli Lilly lost around $86 billion in valuation, partially due to sagging investor enthusiasm and political pricing pressure. Despite this set back, the company's combination of financial strength, groundbreaking products, and robust demand puts it in a category of its own."
Eli Lilly's GLP-1 weight-loss and diabetes drugs, including Mounjaro and newly approved Zepbound, have become blockbusters generating billions in sales and driving substantial stock gains. The stock surged more than 50% year-to-date in 2024 before declining about 8.6% in 2025, yet remained among top-performing large-cap companies. Established products like Verzenio, Trulicity, Jardiance, and Taltz reported double-digit growth. The pipeline includes mirikizumab for Crohn's disease and donanemab for Alzheimer's, indicating further upside. The company trades at over 30 times forward earnings, experienced an $86 billion valuation loss in 2025, but retains strong demand and financial strength.
Read at 24/7 Wall St.
Unable to calculate read time
Collection
[
|
...
]